Lexaria Bioscience Corp (LEXX)

Name: Lexaria Bioscience Corp Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-11-30

Latest Quarter

2025-11-30

Revenue

$0.0

Net Income

-$1.6M

Operating Margin

N/A

Free Cash Flow

-$10.5M

Debt / Assets

37.7%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Lexaria Bioscience Corp (LEXX).
Income Statement (Quarterly)	2025-11-30	2025-02-28	2024-11-30	2024-08-31
Revenue	0	174,000	183,923	84,000
Cost of Revenue	24,197	0	2,720	0
Gross Profit	-24,197	174,000	181,203	84,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	878,094	1,239,096	918,690	1,319,858
Operating Expenses	1,549,434	2,925,012	2,871,910	2,287,064
Operating Income	-1,573,631	-2,751,012	-2,690,707	-2,203,064
Interest Expense	0	0	0	0
Income Before Tax	-1,595,712	-2,713,212	-2,703,699	-2,186,571
Income Tax Expense	1,791	3,760	0	0
Net Income	-1,595,007	-2,713,212	-2,703,699	-2,184,790
Per Share
EPS	-0.07	-0.15	-0.16	-0.17
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Lexaria Bioscience Corp (LEXX).
Income Statement (Annual)	2025-08-31	2024-08-31	2023-08-31	2022-08-31	2021-08-31
Revenue	705,923	464,278	226,208	255,397	722,738
Cost of Revenue	118,572	4,822	31,500	71,841	175,346
Gross Profit	587,351	459,456	194,708	183,556	547,392
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	3,981,967	3,852,021	3,062,009	5,724,534	4,971,349
Operating Expenses	12,220,724	6,212,586	6,728,730	7,567,209	6,234,244
Operating Income	-11,633,373	-5,753,130	-6,534,022	-7,383,653	-5,686,852
Interest Expense	0	0	0	0	0
Income Before Tax	-11,911,434	-5,808,654	-6,712,525	-7,383,653	-4,164,148
Income Tax Expense	0	0	0	-114,329	0
Net Income	-11,901,841	-5,795,345	-6,664,899	-7,269,324	-4,027,006
Per Share
EPS	-0.66	-0.47	-1.01	-1.24	-0.95
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Lexaria Bioscience Corp (LEXX).
Balance Sheet (Quarterly)	2025-08-31	2024-08-31	2023-08-31	2022-08-31
Assets
Cash and Cash Equivalents	1,802,123	6,499,885	1,352,102	5,813,218
Short Term Investments	165,360	55,807	125,642	347,335
Net Receivables	368,358	154,477	175,245	201,784
Inventory	0	0	1	38,418
Total Current Assets	3,468,345	7,897,986	2,199,772	6,977,516
Property Plant Equipment	334,945	389,552	421,589	367,949
Goodwill and Intangibles	307,818	516,676	462,625	488,462
Total Assets	4,175,121	8,867,789	3,083,986	7,833,927
Liabilities
Account Payables	1,365,044	371,354	225,038	57,150
Short Term Debt	30,417	28,047	27,794	42,587
Total Current Liabilities	1,493,463	1,099,419	267,735	194,036
Long Term Debt	78,903	109,319	136,173	7,401
Total Liabilities	1,572,366	1,208,738	403,908	201,437
Shareholders Equity
Retained Earnings	-63,460,613	-51,558,772	-45,763,427	-39,098,528
Total Shareholders Equity	2,989,697	8,036,400	3,044,118	7,948,904

Balance sheet annual history for Lexaria Bioscience Corp (LEXX).
Balance Sheet (Annual)	2025-08-31	2024-08-31	2023-08-31	2022-08-31	2021-08-31
Assets
Cash and Cash Equivalents	1,802,123	6,499,885	1,352,102	5,813,218	10,917,797
Short Term Investments	165,360	55,807	125,642	347,335	833,841
Net Receivables	368,358	154,477	175,245	201,784	342,401
Inventory	0	0	1	38,418	29,648
Total Current Assets	3,468,345	7,897,986	2,199,772	6,977,516	12,442,940
Property Plant Equipment	334,945	389,552	421,589	367,949	459,254
Goodwill and Intangibles	307,818	516,676	462,625	488,462	364,623
Total Assets	4,175,121	8,867,789	3,083,986	7,833,927	13,266,817
Liabilities
Account Payables	1,365,044	371,354	225,038	57,150	99,668
Short Term Debt	30,417	28,047	27,794	42,587	47,330
Total Current Liabilities	1,493,463	1,099,419	267,735	194,036	153,276
Long Term Debt	78,903	109,319	136,173	7,401	49,989
Total Liabilities	1,572,366	1,208,738	403,908	201,437	203,265
Shareholders Equity
Retained Earnings	-63,460,613	-51,558,772	-45,763,427	-39,098,528	-31,829,204
Total Shareholders Equity	2,989,697	8,036,400	3,044,118	7,948,904	13,265,637

Cash flow quarterly history for Lexaria Bioscience Corp (LEXX).
Cash Flow Statement (Quarterly)	2025-08-31	2024-08-31	2023-08-31	2022-08-31
Operating Activities
Net Income	-11,911,434	-5,808,654	-6,712,525	-7,383,653
Depreciation & Amortization	87,825	76,153	145,397	141,315
Stock Based Compensation	859,494	492,236	170,382	752,591
Change in Working Capital	195,576	106,556	143,264	-351,475
Operating Cash Flow	-10,450,387	-4,959,003	-5,881,237	-4,879,339
Investing Activities
Capital Expenditure	-24,643	-43,017	-169,610	-131,448
Investments	-24,646	0	-169,610	-131,448
Investing Cash Flow	-243,019	-188,605	-169,610	-180,640
Financing Activities
Debt Repayment	0	0	0	-44,600
Common Stock Issued/Repurchased	6,046,163	4,208,731	1,589,731	0
Dividends Paid	0	0	0	0
Financing Cash Flow	6,046,163	10,315,207	1,589,731	-44,600
Summary
Free Cash Flow	-10,475,030	-5,002,020	-6,050,847	-5,010,787
Net Change in Cash	-4,697,762	5,147,783	-4,461,116	-5,104,579

Cash flow annual history for Lexaria Bioscience Corp (LEXX).
Cash Flow Statement (Annual)	2025-08-31	2024-08-31	2023-08-31	2022-08-31	2021-08-31
Operating Activities
Net Income	-11,911,434	-5,808,654	-6,712,525	-7,383,653	-4,186,148
Depreciation & Amortization	87,825	76,153	145,397	141,315	147,597
Stock Based Compensation	859,494	492,236	170,382	752,591	410,007
Change in Working Capital	195,576	106,556	143,264	-351,475	63,526
Operating Cash Flow	-10,450,387	-4,959,003	-5,881,237	-4,879,339	-3,989,678
Investing Activities
Capital Expenditure	-24,643	-43,017	-169,610	-131,448	-79,493
Investments	-24,646	0	-169,610	-131,448	0
Investing Cash Flow	-243,019	-188,605	-169,610	-180,640	193,880
Financing Activities
Debt Repayment	0	0	0	-44,600	-66,694
Common Stock Issued/Repurchased	6,046,163	4,208,731	1,589,731	0	9,471,497
Dividends Paid	0	0	0	0	0
Financing Cash Flow	6,046,163	10,315,207	1,589,731	-44,600	13,419,846
Summary
Free Cash Flow	-10,475,030	-5,002,020	-6,050,847	-5,010,787	-4,069,171
Net Change in Cash	-4,697,762	5,147,783	-4,461,116	-5,104,579	9,624,048